Key statistics
On Monday, Savara Inc (SVRA:NSQ) closed at 3.74, 20.06% above the 52 week low of 3.12 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.85 |
---|---|
High | 3.86 |
Low | 3.70 |
Bid | 3.66 |
Offer | 3.82 |
Previous close | 3.82 |
Average volume | 1.14m |
---|---|
Shares outstanding | 164.60m |
Free float | 156.74m |
P/E (TTM) | -- |
Market cap | 628.77m USD |
EPS (TTM) | -0.4317 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 21:00 BST.
More ▼
Press releases
- Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
- Savara Announces New Employment Inducement Grant
- Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
- Savara to Host Analyst and Investor Webinar on September 30, 2024
- Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
- Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
- Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
More ▼